Get the Stockscreener App
34.66
0.30%
-0.0575
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Axogen Inc stock is traded at $34.66, with a volume of 526.28K.
It is down -0.30% in the last 24 hours and up +5.53% over the past month.
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
See More
Previous Close:
$34.72
Open:
$34.94
24h Volume:
526.28K
Relative Volume:
0.57
Market Cap:
$1.74B
Revenue:
$203.27M
Net Income/Loss:
$-4.66M
P/E Ratio:
-346.62
EPS:
-0.1
Net Cash Flow:
$3.47M
1W Performance:
+8.61%
1M Performance:
+5.53%
6M Performance:
+158.90%
1Y Performance:
+93.05%
1-Day Range:
$34.43
$35.50
1-Week Range:
$31.50
$35.50
52-Week Range:
$9.215
$35.50
Axogen Inc Stock (AXGN) Company Profile
Name
Axogen Inc
Sector
Industry
Phone
(386) 462-6817
Address
13631 PROGRESS BLVD., ALACHUA, FL
Compare AXGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AXGN
Axogen Inc
|
34.63 | 1.74B | 203.27M | -4.66M | 3.47M | -0.10 |
|
ABT
Abbott Laboratories
|
107.08 | 189.14B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
BSX
Boston Scientific Corp
|
93.22 | 138.74B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
355.58 | 136.52B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
101.31 | 129.06B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.78 | 48.90B | 5.88B | 1.34B | 799.60M | 2.3489 |
Axogen Inc Stock (AXGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-01-25 | Initiated | Mizuho | Outperform |
| Mar-17-25 | Initiated | Lake Street | Buy |
| Jul-01-24 | Initiated | Raymond James | Outperform |
| Nov-11-22 | Resumed | Jefferies | Buy |
| May-09-22 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-11-22 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-23-20 | Initiated | Guggenheim | Buy |
| Jun-16-20 | Resumed | Cantor Fitzgerald | Overweight |
| May-07-20 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-02-20 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-07-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-12-19 | Initiated | Canaccord Genuity | Buy |
| Mar-02-18 | Reiterated | Lake Street | Buy |
| Jan-05-18 | Resumed | Cantor Fitzgerald | Overweight |
| Nov-30-17 | Initiated | Jefferies | Buy |
| Nov-21-17 | Reiterated | Lake Street | Buy |
| Jul-31-17 | Initiated | Leerink Partners | Outperform |
| Jun-30-17 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-06-17 | Initiated | ROTH Capital | Buy |
| Nov-22-16 | Upgrade | Lake Street | Hold → Buy |
| Nov-07-16 | Reiterated | Wedbush | Outperform |
| Nov-03-16 | Downgrade | Lake Street | Buy → Hold |
| Aug-04-16 | Reiterated | Wedbush | Outperform |
| May-14-14 | Initiated | Dawson James | Buy |
| Oct-31-13 | Reiterated | Ladenburg Thalmann | Buy |
View All
Axogen Inc Stock (AXGN) Latest News
Axogen stock hits 52-week high at 34.79 USD By Investing.com - Investing.com Canada
AxoGen (NASDAQ:AXGN) Sets New 52-Week High Following Analyst Upgrade - MarketBeat
Axogen stock hits 52-week high at 34.79 USD - Investing.com
Income Plays: Is DESP on track to beat earningsRate Hike & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Axogen, Inc. (NASDAQ:AXGN) On The Verge Of Breaking Even - 富途牛牛
A Look At Axogen (AXGN) Valuation After Its Upsized US$124 Million Equity Offering - Yahoo Finance
Axogen Upsized Equity Raise Shifts Debt Profile And Valuation Focus - Sahm
Is Axogen Inc.’s growth already priced inJuly 2025 Technicals & Fast Entry and Exit Trade Plans - mfd.ru
AxoGen (NASDAQ:AXGN) Rating Increased to Strong-Buy at Wall Street Zen - MarketBeat
Axogen (AXGN) Is Up 5.8% After Upsized Equity Raise and Debt PaydownWhat's Changed - Yahoo Finance
AxoGen Announces Equity Offering to Repay Term Loan - TipRanks
Axogen Signs Underwriting Agreement With Wells Fargo Securities and Mizuho Securities USA - TradingView
Axogen (AXGN) prices stock offering and targets $69.7M term loan payoff - Stock Titan
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Ardelyx (ARDX) and AxoGen (AXGN) - The Globe and Mail
AxoGen (NASDAQ:AXGN) Shares Gap DownTime to Sell? - MarketBeat
Axogen plans $85 million stock offering to repay debt By Investing.com - Investing.com Australia
Axogen stock dips after pricing $124M offering - MSN
Axogen (AXGN) Increases Stock Offering to $124 Million - GuruFocus
Axogen (AXGN) Shares Decline After Upsized Public Offering - GuruFocus
Axogen prices upsized public offering of common stock at $31 per share - Investing.com Nigeria
Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock - The Manila Times
Surgical nerve repair company Axogen prices $124M stock sale to pay off term loan - Stock Titan
Axogen announces proposed $85M public stock offering; shares down - MSN
Axogen stock falls after $85 million share offering announcement By Investing.com - Investing.com Nigeria
Axogen stock falls after $85 million share offering announcement - Investing.com
Axogen plans $85 million stock offering to repay debt - Investing.com
Surgical device maker Axogen falls on stock offering plans - TradingView — Track All Markets
Axogen Inc Files For Mixed Shelf Offering Size Not Disclosed - TradingView
Axogen, Inc. Plans $85 Million Public Offering of Common Stock - Quiver Quantitative
Axogen Announces Proposed Public Offering of Common Stock - GlobeNewswire
Axogen plans $85M stock sale to repay loan and fund operations - Stock Titan
Did Strong 2025 Revenue Guidance Just Shift Axogen's (AXGN) Nerve Repair Investment Narrative? - simplywall.st
Understanding Momentum Shifts in (AXGN) - Stock Traders Daily
Assessing Axogen (AXGN) Valuation After FDA Approval And Higher 2025 Revenue Guidance - Sahm
AxoGen, Inc. (AXGN) Stock Analysis: A Promising 18.51% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
AxoGen Touts Post-BLA Growth Plan, 75%+ Gross Margin Outlook at J.P. Morgan Healthcare Conference - MarketBeat
Axogen CEO Axed 25,000 Shares From His Direct Holdings - The Globe and Mail
Stock Analysis: How Axogen Inc stock compares to growth peersGap Up & Low Drawdown Trading Techniques - Bộ Nội Vụ
AxoGen stock gains as Canaccord reiterates Buy rating on strong results By Investing.com - Investing.com South Africa
AxoGen stock gains as Canaccord reiterates Buy rating on strong results - Investing.com Canada
Primoris Wealth Advisors LLC Boosts Holdings in AxoGen, Inc. $AXGN - MarketBeat
Axogen Announces Strong Preliminary Fourth-Quarter 2025 Revenue Growth - The Globe and Mail
Why Axogen (AXGN) Is Up 5.5% After Strong Preliminary 2025 Revenue Guidance And What's Next - simplywall.st
Axogen, Inc. Reports Strong Preliminary Fourth Quarter and Full-Year 2025 Financial Results - Quiver Quantitative
Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025 - marketscreener.com
AxoGen, Inc. (NASDAQ:AXGN) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Axogen Inc Stock (AXGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.90%
0.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):